Sponsors

‘The biggest and best yet’ – IBMS Congress hailed a success

Pathology in Practice editor Andy Myall presents a quick wrap up of the 2023 IBMS Congress, including some thoughts on the event and the Institute’s key activities from Chief Executive David Wells.

IBMS Chief Executive David Wells was unequivocal in hailing the 2023 Congress a success, calling it: “The biggest and best yet.” The Institute’s major biennial event made a triumphant return to its regular September slot, after the 2021 event was pushed into spring 2022 by the long tail of the COVID-19 pandemic. The four days saw an impressive 3,200 delegates attend, joined by around 1,000 people present for the trade show, generating a buzz across the duration.

The educational programme – heavily featured across previous issues of Pathology in Practice – was a major learning opportunity, with in excess of 400 presentations across 19 topics. These included all the disciplines within laboratory science, as well as plenary sessions, a programme for biomedical support staff, and further programmes covering politics, wellbeing, education and training, as well as quality and management.

Session highlights

Log in or register FREE to read the rest

This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text. If you don't already have an account, please register with us completely free of charge.

Latest Issues

The Power to Disrupt - Clinical Diagnostics Expo UK

15 Hatfields
16 September, 2024

Microbe Conference 2024

Crowne Plaza Hotel, Sheffield, UK
20-22 September, 2024

Cardiac Marker Dialogues: Cardiac Biomarkers in Real Time – Experiences and Opportunities

Hilton Glasgow, 1 William Street, Glasgow, Scotland, G3 8HT
26-27 September, 2024

The British Association for Cytopathology Annual Scientific Meeting

Aztec Hotel and Spa, Bristol, BS32 4TS
18 October, 2024

UK NEQAS: Navigating Quality Standards in Point of Care Testing

The Hyatt Regency Hotel, Birmingham, UK
23 October, 2024